Start with the big picture: what is working, what has failed, where the strongest hope is, and which unanswered questions could unlock the next step toward prevention, durable control, and cures.
Get the short, plain-English progress report for Cancer, Celiac Disease, and Alzheimer's/Dementia - including when research is moving but a new public claim is not ready yet.
Short answer: There is no single cure for all cancers. Some cancers are already curable for many people, while others remain difficult because cancer is many diseases with different ways of surviving and escaping treatment. Our job is to track what works, learn from what failed, and identify the next experiment most likely to reduce uncertainty.
Our plain-English rule: Before the technical detail, every public research update should answer five questions: What happened? Why does it matter? How sure are we? What would prove it wrong? What happens next?
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Participants ages 1 Year to 30 Years with Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-22
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-10-22
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Participants ages 18 Years to 123 Years with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-21
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-10-21
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Adult and pediatric patients with high-risk neuroblastoma (a cancer arising from immature nerve cells, most common in young children) who showed at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy, enrolled in the single-arm Study 3b and compared against an external control group drawn from a separate NCI/Children's Oncology Group trial (Study ANBL0032).
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy, to reduce the risk of relapse.
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy (Journal of Clinical Oncology). DOI 10.1200/JCO.24.00546, PMID 38917371.
Adults with locally advanced pancreatic adenocarcinoma, randomized to Tumor Treating Fields (TTFields) plus gemcitabine/nab-paclitaxel chemotherapy or chemotherapy alone, in the randomized, open-label, phase 3 PANOVA-3 trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with locally advanced pancreatic cancer, used concomitantly with gemcitabine and nab-paclitaxel.
Decision date
2026-02-11
Access notes
A DEVICE approval, not a drug approval -- disclosed as such, not conflated with a pharmaceutical regulatory action.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (Journal of Clinical Oncology). DOI 10.1200/JCO-25-00746.
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or other large B-cell lymphoma after two or more prior lines of systemic therapy, enrolled in the dose-expansion cohort of the single-arm, open-label, phase 1/2 EPCORE NHL-1 trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) and high-grade B-cell lymphoma, after two or more lines of systemic therapy.
Biomarker requirement
CD20-expressing B-cell lymphoma (target of the bispecific antibody; not a patient-selection biomarker test)
Decision date
2023-05-19
Access notes
Requires a step-up dosing schedule and monitoring for cytokine release syndrome, particularly around the first doses.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial (Journal of Clinical Oncology). DOI 10.1200/JCO.22.01725, PMID 36548927.
Adults with platinum-resistant, PD-L1-positive (CPS >=1) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who had received one to two prior lines of systemic therapy, randomized to pembrolizumab plus paclitaxel (+/- bevacizumab) or placebo plus paclitaxel (+/- bevacizumab), in the randomized, double-blind, phase 3 ENGOT-ov65/KEYNOTE-B96 trial conducted at 187 sites in 25 countries.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS >=1), who have received one to two prior lines of systemic therapy.
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study (The Lancet). DOI 10.1016/S0140-6736(26)00602-1, PMID 41974150.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Research does not always move through every step in order — some steps are skipped, repeated, or run in parallel, and a promising early result does not guarantee it will reach later stages. This is a general orientation, not a prediction about any specific discovery.
1Laboratory researchStudies in cells or tissue samples, not yet in a living organism.
2Preclinical (animal) researchStudies in animal models, before any human is involved.
3Early human researchThe first small studies in people, often focused on safety.
4Phase 1 trialA small trial testing safety and dosing in people.
5Phase 2 trialA larger trial testing whether a treatment appears to work and is reasonably safe.
6Phase 3 trialA large trial comparing a treatment against the current standard, often across many sites.
7Regulatory reviewA regulator (such as the FDA) reviews trial results to decide whether to approve a treatment for a specific, stated use.
8Clinical / guideline contextClinical guideline bodies decide whether and how an approved treatment fits into standard care.